1. 819Daclatasvir in Combination with Peginterferon Alfa-2a and Ribavirin for Treatment-Naive Patients with HCV Genotype 4 Infection: Phase 3 COMMAND-4 Results. (December 2014) Authors: Hézode, Christophe; Alric, Laurent; Brown, Ashley; Hassanein, Tarek; Rizzetto, Mario; Buti, Maria; Bourliere, Marc; Thabut, Dominique; Molina, Esther; Mcphee, Fiona; Liu, Zhaohui; Yin, Philip; Hughes, Eric; Treitel, Michelle Journal: Open forum infectious diseases Issue: Volume 1(2014)Supplement 1 Page Start: S233 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 821Daclatasvir and Asunaprevir Plus Peginterferon Alfa-2a and Ribavirin in Patients With HCV Genotype 1 or 4 Infection: Phase 3 HALLMARK-QUAD Results. (December 2014) Authors: Jensen, Donald M.; Sherman, Kenneth; Hezode, Christophe; Pol, Stanislas; Zeuzem, Stefan; De Ledinghen, Victor; Tran, Albert; Elkhashab, Magdy; Younes, Ziad H; Kugelmas, Marcelo; Mauss, Stefan; Everson, Gregory T.; Luketic, Velimir; Vierling, John; Serfaty, Lawrence; Brunetto, Maurizia; Heo, Jeong... Journal: Open forum infectious diseases Issue: Volume 1(2014)Supplement 1 Page Start: S234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS‐650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor. Issue 9 (28th January 2015) Authors: Mosure, Kathleen W.; Knipe, Jay O.; Browning, Marc; Arora, Vinod; Shu, Yue‐Zhong; Phillip, Thomas; Mcphee, Fiona; Scola, Paul; Balakrishnan, Anand; Soars, Matthew G.; Santone, Kenneth; Sinz, Michael; Donovan, Maureen D.; Langguth, Peter; Polli, James E.; Tamai, Ikumi; Vig, Balvinder; Yu, Lawrence X. Journal: Journal of pharmaceutical sciences Issue: Volume 104:Issue 9(2015:Sep.) Page Start: 2813 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗